You are here

P&T® Journal contents for October 2004

Features

Editor’s Memo
Sometimes “special” issues just happen.
Sonja Sherritze
Reflections
Dr. Lawless presents a timely tribute to the late Dr. Crick, who discovered the double helix and DNA with a little help from his friends.
Grant D. Lawless, MD, RPh
Meeting Highlights
Some advances in urology include the use of leuprolide and zoledronic acid for prostate cancer; lidocaine for therapy-induced penile aching; alprostadil, vardenafil, and tadalafil for erectile dysfunction; tolterodine and solifenacin for overactive bladder; and a gelatin sealant for tubeless percutaneous nephrolithotomy.
Lawrence M. Prescott, PhD
The antiepileptic agent gabapentin (Neurontin®) can be helpful in treating a painful condition that commonly affects older patients.
Brett Stacey, MD, Bruce Parsons, MD, PhD, Sue Huang, Shoshana Peyser, PhD, and Ellen Dukes, PhD
Continuing Education Credit
The authors review the guidelines for and the complexities of administering warfarin, a commonly used antithrombotic agent.
Randolph E. Regal, BS, PharmD, and Vanna Tsui, PharmD

Departments

Editorial
Karl Matuszewski MS, PharmD, describes a physician’s account of his experience with coronary artery bypass graft surgery.
Karl Matuszewski MS, PharmD
Medication Errors
Matthew Grissinger, RPh, FASCP, stresses the importance of appropriate use of fibrinolytic agents in patients with acute myocardial infarction.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Stephen Barlas discusses the “formulary fireworks” surrounding the draft Medicare guidelines issued by the United States Pharmacopeia.
Stephen Barlas
P&T presents the latest information about FDA approvals, drug indications, industry updates, and new devices
Drug Forecast
Drs. Gonzales and Edwards review alfuzosin HCl (Uroxatral®) for the treatment of benign prostatic hyperplasia.
Michelle Gonzales, PharmD, and Deidree Edwards, PharmD